J

ust two weeks after a rare rebuke from the Food and Drug Administration derailed Alkermes’s treatment for serious depression, the company has convinced the agency to change its mind and give the drug a chance.

On April 2, Alkermes said the FDA refused to even consider its approval application for a drug called ALKS-5461, citing “insufficient evidence of overall effectiveness” and sending the company’s share price down about 20 percent. On Monday, Alkermes CEO Richard Pops said the agency had reversed course, correcting a “misunderstanding” and putting ALKS-5461 on track for a yes or no decision by Jan. 31.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.